Please login to the form below

Not currently logged in
Email:
Password:

Former AZ oncology head joins Innate Pharma

Dr Mondher Mahjoubi becomes chairman of the executive board at the French biotech

Innate Pharma Mondher MahjoubiDr Mondher Mahjoubi, formerly AstraZeneca's head of oncology, has moved to lead French biotech Innate Pharma.

Innate appointed Dr Mahjoubi as chairman of the executive board from 30 December last year, succeeding co-founder Dr Hervé Brailly who transitions to chairman of the supervisory board.

Dr Mahjoubi brings over 20 years of clinical development, marketing and strategy experience to the position, most recently from AstraZeneca where he was senior vice president and therapeutic area head for oncology, global product and portfolio strategy.

Prior to this, he was senior vice president of global product strategy at Roche's Genentech unit, and has also held senior positions in oncology at Aventis and Sanofi.

Dr Mahjoubi said: “This is a really great opportunity for me to be joining Innate Pharma as chairman of the executive board.

“Immuno-oncology is transforming in depth the way we can treat cancer patients. Building on a unique and differentiated expertise in innate immunity, Innate Pharma has been a pioneer in immuno-oncology.

“The team has demonstrated its impressive ability to deliver in research, discovery and exploratory development, and the company has now reached a key inflection point to emerge as a major player for the second wave of immuno-oncology agents.

“I look forward to working closely with Hervé Brailly, the board and the team as we build Innate Pharma into a global, fully-integrated company, working in the best interests of patients, employees, shareholders and other stakeholders."

11th January 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's premier medical animation company. Over the past 20 years we have created over 350 mechanism-of-action (MoA)...

Latest intelligence

Devil_in_the_edetail.png
The Devil is in the E-Detail
All too often, pharma companies are relying on the e-detailing approach, and missing a big opportunity to engage with their customers, build relationships, and add value....
Medical Translations: Why you need to get it right the first time
British and American senior medical executives admit to image and reputation being at risk because of misinterpreted cultural references or linguistic errors....
Digital disruption
How pharma is keeping up with the pace of change...

Infographics